ClinicalTrials.gg
RecruitingNCT07650240SPARKLEUpdated Sep 18, 2026

Study of PSMA-targeted Therapy and Androgen Receptor Suppression in Low-volume Metastatic ProstatE Cancer: SPARKLE Trial

A Phase 2 interventional study of Abiraterone Acetate and Biospecimen Collection in Recurrent Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8 and Castration-Sensitive Prostate Cancer, sponsored by Mayo Clinic. Recruiting at 1 site in United States. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-18.

Sponsored by Mayo Clinic · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Aug 2026; still recruiting 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
202
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 98 studies testing Abiraterone Acetate in Prostatic Neoplasms — 12 open to participants now, 29 under way, 4 of them phase 3. Abiraterone Acetate · Prostatic Neoplasms.

Planned enrollment
17th of 98
202 · median 56
Started
2026
the only one that year
Phase 2
59 of 98
9 open now
Primary completion
2030-12
later than 27 of 28 live
Registered
98th of 98
by date

Among the 98 studies testing Abiraterone Acetate in Prostatic Neoplasms, this one is the 17th largest by planned enrollment, is the only one that started in 2026, is one of 59 in phase 2, reaches primary completion later than 27 of the 28 other live ones, and was the 98th registered.

Prostatic Neoplasms

7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

12 of the 98 studies testing Abiraterone Acetate in Prostatic Neoplasms are open now, in 8 countries. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 12 open studies →

About Abiraterone Acetate

Abiraterone Acetate: first FDA approval 2011 (ZYTIGA), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 98 studies testing Abiraterone Acetate in Prostatic Neoplasms, or all of them as a file.
02

Study summary

This phase II trial tests leuprolide acetate alone versus in combination with 177Lu-PSMA-617, with or without abiraterone acetate and prednisone, for the treatment of hormone-sensitive prostate cancer has spread to a limited number of anatomic sites at the time of initial diagnosis (de novo low volume metastasis) or that has come back after a period of improvement (recurrent). Standard of care treatment for prostate cancer usually includes androgen deprivation therapy, with or without abiraterone acetate and prednisone. Leuprolide acetate is a form of androgen deprivation therapy. It blocks the body from making testosterone (a male hormone) and estradiol (a female hormone). It may stop the growth of prostate cancer cells that need testosterone to grow. 177Lu-PSMA-617 is a type of radioconjugate drug. Upon administration, vipivotide tetraxetan targets and binds to prostate specific membrane antigen (PSMA)-expressing tumor cells. Upon binding, PSMA-expressing tumor cells are destroyed by 177Lu through the specific delivery of radiation. PSMA, a tumor-associated antigen and type II transmembrane protein, is overexpressed on prostate tumor cells. Abiraterone acetate is a type of anti-androgen drug. It blocks tissues from making androgens (male hormones), such as testosterone. This may cause the death of cancer cells that need androgens to grow. Prednisone is in a class of medications called corticosteroids. It is used to reduce inflammation and lower the body's immune response to help lessen the side effects of chemotherapy drugs. Giving 177Lu-PSMA-617 in combination with leuprolide acetate, with or without abiraterone acetate and prednisone, may be more effective at treating patients with recurrent or de novo low volume metastatic hormone-sensitive prostate cancer than giving leuprolide acetate alone.

03

Conditions studied

  • Recurrent Prostate Adenocarcinoma
  • Stage IVB Prostate Cancer AJCC v8
  • Castration-Sensitive Prostate Cancer
  • Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
  • Prostate Cancer
  • Prostate Adenocarcinoma
  • Adenocarcinoma of the Prostate
  • Localized Prostate Carcinoma
  • Metastatic Prostate Cancer
  • Metastatic Prostate Adenocarcinoma
  • Advanced Prostate Cancer
  • Advanced Prostate Adenocarcinoma

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male patients aged 18 years or older
  • Signed must be obtained prior to participation in the study
  • confirmed adenocarcinoma of the prostate
  • Prior treatment with radical prostatectomy or radiation therapy for localized disease is required
  • Prior treatment with ADT or androgen receptor pathway inhibitor (ARPI) or cytotoxic chemotherapy is permitted if:

    • The last treatment > 12 months from enrollment on the trial
    • The duration of treatment is less than 3 months and no evidence of disease progression on treatment
  • Disease detected on PSMA PET/CT scan [PSMA-avid low volume (LVM)]. Patients with standardized uptake value maximum (SUVMax) lesion/liver >1 [molecular imaging PSMA (miPSMA) score of 2] or lesion/parotid > 1 (miPSMA score of 3) would be included. PET scanners used in the study will comply with current guidelines established by the European Association of Nuclear Medicine (EANM) Research Limited (Ltd) (EARL) for harmonizing PET/CT image acquisition and reconstruction
  • Patients with hormone sensitive low volume metastatic disease (LVM); either de novo metastatic or recurrent disease. LVM, as assessed on PSMA PET/CT is defined as:

    • =\< 10 total metastatic spots

      • Lymph nodes with short axis of =\< 2.5 cm
      • Total tumor volume (TTV) \< 200 mL
    • =\< 4 bone metastases
    • No brain or liver metastases
  • (ECOG) performance 0 - 2
  • >= 9 g/dL
  • count >= 100,000/mm\^3
  • >= 1,500/mm\^3
  • Serum =\< 1.5 x (ULN)
  • (ALT)/aspartate aminotransferase (AST) =\< 2.5 x ULN
  • Serum creatinine =\< 1.5 x ULN or an estimated (eGFR) >= 50 mL/min/1.73m\^2
  • Able to start therapy within 28 days of screening
  • Expected > 6 months

Exclusion criteria

Exclusion Criteria:

  • PSMA-undetectable disease defined as rising prostate specific antigen (PSA) with absence of PSMA-positive lesions in PSMA PET/CT imaging
  • PSMA-negative disease defined as lesions detected on imaging that are deemed concerning for active cancer with PSMA SUVmax less than liver and meeting specific size criteria: lymph nodes with short axis of >= 2.5 cm, visceral lesions with a solid appearance (soft tissue density) >= 1 cm, and bone metastases with a measurable soft tissue component >= 1 cm
  • Patient with in-field failure (disease recurrence in prostate bed after primary definitive prostatectomy or radiotherapy)
  • Patient with spinal metastatic disease-causing cord compression
  • Patient with prior disease progression on ADT [castration resistance prostate cancer (CRPC)]
  • Prior treatment with ADT or cytotoxic chemotherapy or ARPI within less than 12 months from enrollment on the trial
  • Prior treatment with ADT or ARPI or cytotoxic chemotherapy is permitted only if more than 3 months treatment duration and no evidence of disease progression on treatment
  • Patients with severe [ (CTCAE) grade > 2] xerostomia
  • Patients with well documented history of myelosuppression or renal disease that might impair their participation in the trial per medical advice
  • Diagnosed with other that are expected to alter or may interfere with disease assessment. However, participants with a prior history of malignancy that has been adequately treated non-melanoma skin cancer, superficial bladder cancer are eligible
  • Estimated life expectancy \< 6 months
  • Concurrent serious medical co-morbidities as determined by study investigator and expected to impair participation in the study

    • Subjects with female partners of are required to use effective, medically acceptable methods of (e.g., spermicide in conjunction with a barrier such as a condom or sexual abstinence) while on this study, and for 14 weeks after the last dose of 177Lu-PSMA-617
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
202 participants (estimated)

Study arms

  • Experimental
    Arm A1 (177Lu-PSMA-617, iADT)

    Patients receive 177Lu-PSMA-617 IV once every 6 weeks and leuprolide acetate subcutaneous (SC) once every 3 months (Q3M). Treatment continues for up to 6 months in the absence of disease progression or unacceptable toxicity. Patients also undergo PSMA PET/CT and collection of blood samples throughout the trial and undergo SPECT on study.

    Procedure: Biospecimen Collection · Drug: Leuprolide Acetate · Drug: Lutetium Lu 177 Vipivotide Tetraxetan · Procedure: PSMA PET-CT Scan · Other: Quality-of-Life Assessment · Procedure: Single Photon Emission Computed Tomography

  • Active comparator
    Arm A2 (iADT)

    Patients receive leuprolide acetate SC Q3M for up to 6 months in the absence of disease progression or unacceptable toxicity. Patients also undergo PSMA PET/CT and collection of blood samples throughout the trial.

    Procedure: Biospecimen Collection · Drug: Leuprolide Acetate · Procedure: PSMA PET-CT Scan · Other: Quality-of-Life Assessment

  • Experimental
    Arm B1 (177Lu-PSMA-617, iADT, iAA, P)

    Patients receive 177Lu-PSMA-617 IV every 6 weeks, leuprolide acetate SC Q3M, abiraterone acetate PO (by mouth) QD (once a day) and prednisone PO BID (twice a day). Treatment continues for up to 6 months in the absence of disease progression or unacceptable toxicity. Patients also undergo PSMA PET/CT and collection of blood samples throughout the trial and undergo SPECT on study.

    Drug: Abiraterone Acetate · Procedure: Biospecimen Collection · Drug: Leuprolide Acetate · Drug: Lutetium Lu 177 Vipivotide Tetraxetan · Drug: Prednisone · Procedure: PSMA PET-CT Scan · Other: Quality-of-Life Assessment · Procedure: Single Photon Emission Computed Tomography

  • Active comparator
    Arm B2 (iADT, iAA, P)

    Patients receive leuprolide acetate SC Q3M, abiraterone acetate PO QD and prednisone PO BID. Treatment continues for up to 6 months in the absence of disease progression or unacceptable toxicity. Patients also undergo PSMA PET/CT and collection of blood samples throughout the trial.

    Drug: Abiraterone Acetate · Procedure: Biospecimen Collection · Drug: Leuprolide Acetate · Drug: Prednisone · Procedure: PSMA PET-CT Scan · Other: Quality-of-Life Assessment

Interventions

  • Given PO

    Also known as: BR9004, BR9004-1, CB 7630, CB-7630, CB7630, JNJ-212082, Yonsa, Zytiga

  • ProcedureBiospecimen Collection

    Undergo collection of blood samples

    Also known as: Biological Sample Collection, Biospecimen Collected, Sample Collection, Specimen Collection

  • DrugLeuprolideStudies of LeuprolideLeuprolide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Given SC

    Also known as: A 43818, A-43818, A43818, Abbott 43818, Abbott-43818, Carcinil, Depo-Eligard, Eligard, Enanton, Enantone, Enantone-Gyn, Fensolvi, Ginecrin, LEUP, Leuplin, Leuprorelin Acetate, Lucrin, Lucrin Depot, Luprodex Depot, Lupron, Lupron Depot, Lupron Depot-3 Month, Lupron Depot-4 Month, Lupron Depot-Ped, Lutrate, Procren, Procrin, Prostap, TAP 144, TAP-144, TAP144, Trenantone, Uno-Enantone, Viadur

  • DrugLutetium (¹⁷⁷Lu) vipivotide tetraxetanStudies of Lutetium (¹⁷⁷Lu) vipivotide tetraxetanLutetium (¹⁷⁷Lu) vipivotide tetraxetan pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Given IV

    Also known as: 177Lu-labeled PSMA-617, 177Lu-PSMA-617, AAA 617, AAA-617, AAA617, Lu177-PSMA-617, Lutetium Lu 177-PSMA-617, LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN, Lutetium-177-PSMA-617, Pluvicto

  • Given PO

    Also known as: .delta.1-Cortisone, 1, 2-Dehydrocortisone, Adasone, Cortancyl, Dacortin, DeCortin, Decortisyl, Decorton, Delta 1-Cortisone, Delta-Dome, Deltacortene, Deltacortisone, Deltadehydrocortisone, Deltasone, Deltison, Deltra, Econosone, Lisacort, Meprosona-F, Metacortandracin, Meticorten, Ofisolona, Orasone, Panafcort, Panasol-S, Paracort, Perrigo Prednisone, PRED, Predicor, Predicorten, Prednicen-M, Prednicort, Prednidib, Prednilonga, Predniment, Prednisone Intensol, Prednisonum, Prednitone, Promifen, Rayos, Servisone, SK-Prednisone

  • ProcedurePSMA PET-CT Scan

    Undergo PSMA PET/CT

    Also known as: PET-CT (PSMA), Prostate-specific Membrane Antigen PET-CT, PSMA PET-CT

  • OtherQuality-of-Life Assessment

    Ancillary studies

    Also known as: Quality of Life Assessment

  • ProcedureSingle Photon Emission Computed Tomography

    Undergo SPECT

    Also known as: Medical Imaging, Single Photon Emission Computed Tomography, Single Photon Emission Tomography, Single-Photon Emission Computed, single-photon emission computed tomography, SPECT, SPECT imaging, SPECT SCAN, SPET, ST, tomography, emission computed, single photon, Tomography, Emission-Computed, Single-Photon

06

What researchers measure

Primary outcomes

  1. Radiographic progression free survival (rPFS)

    Will be evaluated according to prostate specific membrane antigen (PSMA) positron emission tomography (PET) progression (PPP) criteria. Defined as the time from enrollment to documented radiographic progression or death from any cause, whichever occurs first.

    Time frame: At 18 months

Secondary outcomes

  1. Biochemical recurrence free survival (BCR-FS)

    Assessed using PSMA scans. Defined as the time after treatment during which no signs of biochemical recurrence are found.

    Time frame: At 12 months

  2. Treatment-free interval

    Defined as the length of time a patient remains off active systemic therapies while maintaining disease control.

    Time frame: Up to 18 months

  3. Overall survival

    Defined as the time from randomization or enrollment to death from any cause, whichever occurs first.

    Time frame: Up to 3 years

Other outcomes

  1. Quality of life - FACT-P

    Assessed using the Functional Assessment of Cancer Therapy-Prostate (FACT-P) questionnaire, a 39-item questionnaire used to measures Health-Related Quality of Life (HRQOL) in prostate cancer patients. Responses to each question are scored on a 5-point Likert scale ranging from 0 (not at all) to 4 (very much). Possible total scores range from 0-156, with higher scores indicating better QoL. A drop in the FACT-P total score \>5 points will be considered clinically meaningful.

    Time frame: At baseline and then every 3 months up to 1 year

07

Study locations

1 of 1 sites recruiting
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2026 (actual). Primary completion is estimated for Dec 2030, 52 months after the start.

Of 613 non-industry phase 2 interventional studies under Prostatic Neoplasms, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 86. This study's planned 52 months is close to that.

Counting every sponsor, half of 727 studies reached it within 53 months; a quarter within 34 and three quarters within 80.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 10, 2026
First posted
Jun 16, 2026
StartActual
Aug 4, 2026
Primary completionEst.
Dec 30, 2030
CompletionEst.
Dec 30, 2030
Last update
Sep 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07650240
Lead sponsor
Mayo Clinic
Responsible party
Sponsor
First posted
Jun 16, 2026
Start date
Aug 4, 2026
Primary completion
Dec 30, 2030 (estimated)
Completion
Dec 30, 2030 (estimated)
Last update
Sep 18, 2026

Study contacts

Clinical Trials Referral Office
Contact
mayocliniccancerstudies@mayo.edu
855-776-0015
Urology Study Coordinator
Contact
507-422-5076
Matthew K. Tollefson, MD
principal investigator · Mayo Clinic in Rochester

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Abiraterone Acetate · Lutetium (¹⁷⁷Lu) vipivotide tetraxetan · Prednisone

Start the discussion